Navigation Links
Salugen to Present at Nutrition Capital Network's First In-Person Investor Meeting
Date:10/9/2007

Nutrigenomic Company to Present Unique Business Model

SAN DIEGO, Oct. 9 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company and recent consecutive year award winner from the Natural Products Association for its nutritional genetic research, announces today that it has been selected to present at the first annual Nutrition Capital Network investor meeting, October 17, 2007 in San Francisco, CA.

Presenting companies are pre-screened by the Nutrition Capital Network institutional investors for their uniqueness and protectibility of their product or service; strength of business model; experience of the management team and the caliber of the investment proposal. Investors attending this meeting include: The Dannon Company, DuPont, Nestle, PHYSIC Ventures, Rosewood Capital, North Castle Partners, Sherbrooke Capital, Burrill & Co, and many others.

Salugen CEO Brian Meshkin states, "We are honored to present Salugen's unique business to the investment community attending the Nutrition Capital Network inaugural meeting. Salugen's technology has been scientifically and clinically validated by our extensive compilation of peer-reviewed publications, years of research, record of clinical studies, and extensive intellectual property that sets us apart from other companies involved in nutrigenomics. We look forward to the opportunity of sharing our vision with strategic investor partners at the meeting."

Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (http://www.GenoTrim.com), SpaGen (TM) for optimal health and wellness (http://www.SpaGen.com) and Haveos(TM) for substance abuse attenuation.

About Salugen

Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com.


'/>"/>
SOURCE Salugen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ... Exchange: PBT.U), is excited to announce the formation ... on developing preclinical ophthalmology assets through proof of ... anti-inflammatory created by Portage Pharmaceuticals Limited and being ... ocular surface and anterior segment diseases. This agent ...
(Date:11/30/2016)...  Tempus, a technology company focused on supporting ... Cancer Center have partnered to better determine which ... treatment based on next generation genomic and transcriptomic ... research collaboration, Tempus will provide sequencing and analysis ... to Penn. Utilizing next-generation sequencing, machine learning and ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
(Date:11/30/2016)... Park, North Carolina (PRWEB) , ... November 30, 2016 , ... ... approved the names and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine ... a 5-month period of public review, the names earlier proposed by the discoverers have ...
Breaking Biology Technology:
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
Breaking Biology News(10 mins):